Correlation Between Apellis Pharmaceuticals and Axsome Therapeutics

Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Axsome Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Axsome Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Apellis Pharmaceuticals and Axsome Therapeutics, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Axsome Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Axsome Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Axsome Therapeutics.

Diversification Opportunities for Apellis Pharmaceuticals and Axsome Therapeutics

-0.59

Correlation Coefficient

Apellis Pharmaceuticals  Axsome Therapeutics

Excellent diversification

The 3 months correlation between Apellis and Axsome is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Axsome Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Axsome Therapeutics and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Axsome Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Axsome Therapeutics has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Axsome Therapeutics go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Axsome Therapeutics

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to under-perform the Axsome Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Apellis Pharmaceuticals is 1.28 times less risky than Axsome Therapeutics. The stock trades about -0.12 of its potential returns per unit of risk. The Axsome Therapeutics is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest  8,478  in Axsome Therapeutics on December 28, 2024 and sell it today you would earn a total of  3,699  from holding Axsome Therapeutics or generate 43.63% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Apellis Pharmaceuticals  vs.  Axsome Therapeutics

Apellis Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Axsome Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Axsome Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Apellis Pharmaceuticals and Axsome Therapeutics

The main advantage of trading using opposite Apellis Pharmaceuticals and Axsome Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Axsome Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will offset losses from the drop in Axsome Therapeutics' long position.

The idea behind Apellis Pharmaceuticals and Axsome Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.